Tempus, a technology company focused on helping doctors personalize cancer care, and University Hospitals Seidman Cancer Center joined together to improve research and healthcare by making genomic data, advanced molecular analysis and clinical decision support tools available to the hospital’s researchers, physicians and healthcare providers.
An analysis by researchers from the International Agency for Research on Cancer casts doubt on validity of an endpoint used in key studies of multi-cancer detection tests.
